Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight
- PMID: 21149664
- DOI: 10.1200/JCO.2010.32.5290
Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight
Comment on
-
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.J Clin Oncol. 2011 Jan 20;29(3):264-71. doi: 10.1200/JCO.2010.30.8213. Epub 2010 Dec 13. J Clin Oncol. 2011. PMID: 21149659 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials